Zhiwei obtained his PhD degree from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and majored in Pharmacology (2016-2021). During his doctoral study, he mainly focused on the identification of precision therapies in KRAS mutant cancers. He combined the mass spectrometry-based proteomic techniques and bioinformatic analysis including machine learning to subtype the KRAS mutant cancers and identify the subset specific vulnerabilities. In July 2021, Zhiwei joined the Guomics team as a postdoctoral researcher for proteomic big data
research.

Representative Publications
1. Zhiwei Liu #, Yingluo Liu #, Lili Qian, Shangwen Jiang, Xiameng Gai, Shu Ye, Yuehong Chen, Xiaomin Wang, Linhui Zhai, Jun Xu, Congying Pu, Jing Li, Fuchu He, Min Huang, Minjia Tan. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Molecular cell. 2021,81:1-15(First author)
2. JunYu Xu #, Chunchao Zhang #, Xiang Wang #, Linhui Zhai #, Yiming Ma #, Yousheng Mao, Kun Qian, Changqing Sun, Zhiwei Liu, Shangwen Jiang, Minghui Wang, Lin Feng,Lei Zhao, Ping Liu, Bo Wang, Xin Zhao, Hui Xie, Xiaoyun Yang, Liyuan Zhao, Yafei Chang, Jingya Jia, Xijun Wang, Yimin Zhang, Yaru Wang, Yikun Yang, Zhixiang Wu, Longhai Yang, Bin Liu, Teng Zhao, Shengguo Ren, Aihua Sun, Yang Zhao, Wantao Ying, Fei Wang, Guangshun Wang, Yi Zhang, Shujun Cheng, Jun Qin, Xiaohong Qian, Yi Wang, Jing Li, Fuchu He, Ting Xiao, Minjia Tan. Integrative Proteomic Characterization of Human Lung Adenocarcinoma. Cell. 2020, 182: 245–261 (co-author)
3. Xun Huang #, Juan Yan #, Min Zhang #, Yafang Wang #, Yi Chen, Xuhong Fu , Rongrui Wei , Xing-Ling Zheng, Zhiwei Liu, Xiong Zhang , Hong Yang , Bingbing Hao, Yan-Yan Shen, Yi Su, Xiaoji Cong, Min Huang, Minjia Tan, Jian Ding, Meiyu Geng. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Cell. 2018;175(1):186-99 e19. (co-author)